WP
VRTX icon

Waycross Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Waycross Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,951
Closed -$595K – 100
2021
Q2 		$595K Hold
2,951
– – 0.32% 63
2021
Q1 		$634K Hold
2,951
– – 0.35% 67
2020
Q4 		$697K Buy
+2,951
New +$677K 0.43% 56

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Waycross Partners's VRTX Position: Q3 2021 in Review

Waycross Partners sold out of Vertex Pharmaceuticals (VRTX) in Q3 2021, closing a stake of 2,951 shares — an estimated $595K sold.

Waycross Partners first reported a position in VRTX in Q4 2020 and held it in 3 quarters. The position peaked at $697K in Q4 2020. 933 funds tracked by Wall St. Rank hold VRTX as of Q3 2021.

  • Waycross Partners reported no remaining Vertex Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Waycross Partners sold 2,951 Vertex Pharmaceuticals shares in Q3 2021, an estimated $595K.
  • Waycross Partners first reported a position in Vertex Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • Waycross Partners's Vertex Pharmaceuticals position peaked at $697K in Q4 2020.
  • 933 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2021.

Based on Waycross Partners's 13F filing for Q3 2021, filed 10 Nov 2021.